GLP-1 Peptides Explained: How They Work, Who They Help, and How to Get One

A GLP-1 peptide is a prescription medication that mimics glucagon-like peptide-1, a gut hormone that helps lower blood sugar, slow digestion, and reduce appetite. FDA-approved GLP-1 peptides include semaglutide and liraglutide; tirzepatide is a related dual GLP-1/GIP medicine. These drugs are used for type 2 diabetes and, for some products, chronic weight management under clinician supervision 1 2 3.

What is a GLP-1 peptide?

GLP-1 peptides are medications that act on the GLP-1 receptor, a target involved in blood sugar, appetite, and digestion. Natural GLP-1 is broken down within minutes by the DPP-4 enzyme, while prescription GLP-1 medicines are designed to last much longer 4.

The natural GLP-1 hormone

Glucagon-like peptide-1, or GLP-1, is an incretin hormone released by the gut after eating. It tells the pancreas to release insulin when blood sugar is high, lowers glucagon release, slows stomach emptying, and sends fullness signals to the brain 4.

That short life matters. Because DPP-4 breaks down natural GLP-1 quickly, drug developers built longer-acting GLP-1 receptor agonists for type 2 diabetes and, later, chronic weight management 4.

How synthetic GLP-1 peptides mimic it

Synthetic GLP-1 peptides, such as semaglutide and liraglutide, bind the GLP-1 receptor and copy selected actions of the natural hormone. They differ by molecule, route, schedule, label indication, side effects, and contraindications, so the right fit depends on a clinician’s review 1 2 5.

Semaglutide appears as Ozempic for type 2 diabetes, Wegovy for chronic weight management and certain cardiovascular risk reduction uses, and Rybelsus as oral semaglutide for type 2 diabetes 1 2 8. At Chia, compounded semaglutide injections are available through a licensed-provider evaluation and US 503A pharmacy dispensing.

How do GLP-1 peptides work in the body?

GLP-1 receptor agonists work through connected pathways: appetite signaling, slower stomach emptying, glucose-dependent insulin release, and lower glucagon. These effects can support type 2 diabetes care and, for certain products, chronic weight management, but side effects and contraindications need equal attention 1 2 3 4.

Appetite and gastric emptying

GLP-1 medicines can slow how fast food leaves the stomach and can increase fullness signals in the brain. In weight-management trials lasting 68 to 72 weeks, semaglutide and tirzepatide active ingredients were linked with greater average weight loss than placebo; individual results vary 9 10.

The same gut effects can cause problems. Nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux-type symptoms are common across labels and trials, and delayed stomach emptying may affect some oral medicines 1 2 3 9 10.

Insulin and blood sugar

GLP-1 receptor agonists increase insulin release when glucose is high and reduce glucagon, which helps lower blood sugar in type 2 diabetes. This glucose-dependent action lowers, but does not remove, the risk of hypoglycemia, especially when used with insulin or sulfonylureas 1 3 4.

This is why diabetes history matters. A person already using insulin, sulfonylureas, or other glucose-lowering drugs needs a careful medication review before a GLP-1 or GLP-1-related medicine is prescribed 1 3.

Cardiometabolic effects

Some GLP-1 medicines have been studied beyond blood sugar and weight. In the SELECT trial, adults with overweight or obesity and established cardiovascular disease but without diabetes received semaglutide 2.4 mg once weekly, and semaglutide reduced major adverse cardiovascular events compared with placebo; individual results vary 11.

These benefits do not make GLP-1 medicines risk-free. FDA labels include warnings such as pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, hypersensitivity, and thyroid C-cell tumor concerns for some products 1 2 3.

Which GLP-1 peptides are FDA-approved?

FDA-approved GLP-1 medications include several drugs for type 2 diabetes, chronic weight management, or both. The category includes older daily and twice-daily medicines, newer weekly injections, and oral semaglutide; tirzepatide is often discussed with GLP-1s because it acts partly on the GLP-1 receptor 1 2 3 5 6 7 8.

Semaglutide: Ozempic, Wegovy, and Rybelsus

Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus, but those labels are not interchangeable. Ozempic and Rybelsus are approved for type 2 diabetes, while Wegovy is approved for chronic weight management in eligible patients and for reducing certain cardiovascular risks in adults with cardiovascular disease and obesity or overweight 1 2 8.

The FDA-approved starting dose for Wegovy is 0.25 mg once weekly for the first 4 weeks, with gradual label-directed escalation toward maintenance dosing 2. That is label information, not personal dosing advice; nausea, vomiting, diarrhea, constipation, pancreatitis warnings, gallbladder warnings, and thyroid-tumor contraindications still need review 2.

Liraglutide: Victoza and Saxenda

Liraglutide is a GLP-1 receptor agonist sold as Victoza for type 2 diabetes and Saxenda for chronic weight management. FDA labeling for Saxenda includes adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition, along with reduced-calorie diet and increased physical activity 5.

Liraglutide is shorter-acting than weekly semaglutide, so the labeled weight-management product is injected daily 5. Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 5.

Dulaglutide: Trulicity

Dulaglutide, sold as Trulicity, is a weekly GLP-1 receptor agonist approved for type 2 diabetes and for reducing major adverse cardiovascular events in certain adults with type 2 diabetes and cardiovascular disease or multiple cardiovascular risk factors 6. It is not labeled as a chronic weight-management medicine 6.

Dulaglutide can improve glycemic control through glucose-dependent insulin release and lower glucagon, but expectations should stay tied to its label and evidence base 6. Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, pancreatitis warnings, kidney-injury warnings, and the thyroid C-cell tumor contraindication are part of the safety review 6.

Exenatide: Byetta and Bydureon

Exenatide is an older GLP-1 receptor agonist sold as Byetta and Bydureon BCise for type 2 diabetes 7. Byetta is a twice-daily injection, while Bydureon BCise is a once-weekly formulation, which shows how much dosing schedule can differ inside the same drug class 7.

Exenatide’s main role is glycemic control, not chronic weight management as a labeled indication 7. Safety review includes nausea, vomiting, diarrhea, kidney-related cautions, pancreatitis warnings, and injection-site reactions, depending on the formulation 7.

Tirzepatide: Mounjaro and Zepbound

Tirzepatide is not a pure GLP-1 peptide; it is a dual GLP-1/GIP receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and certain obesity-related indications 3. Patients often group tirzepatide with GLP-1s because it includes GLP-1 receptor activity.

In the SURMOUNT-1 trial, adults with obesity or overweight without diabetes received tirzepatide once weekly at study-attributed doses of 5 mg, 10 mg, or 15 mg, and average weight reduction was greater than placebo over 72 weeks; individual results vary 10. Gastrointestinal adverse events were common, especially during dose escalation, and the FDA label includes contraindications for personal or family history of medullary thyroid carcinoma or MEN2 3 10.

At Chia, compounded tirzepatide tablets and injections are available after a licensed-provider evaluation, with microdosing plans available when clinically appropriate.

On the horizon: retatrutide and oral orforglipron

Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors. It is not approved for weight loss, diabetes, or longevity, is not available as a legal compounded prescription, and Chia does not offer it.

In a phase 2 obesity trial, retatrutide was studied at once-weekly doses up to 12 mg and produced greater mean weight reduction than placebo, but gastrointestinal events and heart-rate increases were reported; individual results vary 12. For this one, the honest answer is that the evidence is promising but still investigational.

Orforglipron is an investigational oral non-peptide GLP-1 receptor agonist, so it is not technically a GLP-1 peptide. In a phase 2 trial in adults with obesity or overweight, orforglipron was studied at oral doses from 12 mg to 45 mg daily and showed weight reduction versus placebo, with gastrointestinal adverse events reported 13.

Are GLP-1 peptides the same as Ozempic?

Ozempic is one GLP-1 peptide medication, not the whole category. Ozempic is semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes, while Wegovy is semaglutide approved for chronic weight management and certain cardiovascular risk reduction uses 1 2.

This distinction protects expectations. A clinician should explain the active ingredient, the route, the safety plan, and the pharmacy source, especially when a compounded medication is being considered 15.

How are GLP-1 peptides different from other peptide therapies?

GLP-1 peptides are incretin medicines with large human trials and FDA labels for defined metabolic uses. Other peptide therapies, including BPC-157, CJC-1295, and MOTS-c, target different biology and usually have thinner human evidence, especially for longevity claims 4 14 16 17.

BPC-157 and TB-500

BPC-157 and TB-500 are usually discussed as tissue-repair peptides, but they are not GLP-1 peptides and Chia does not offer them. The mechanism story is mainly about blood-vessel signaling, tendon and muscle repair pathways, gut-barrier biology, and inflammation signaling in preclinical models 14.

The practical expectation should be modest: human outcome data are limited, so claims about injury recovery or longevity should be treated as investigational. Main risks include uncertain product quality from no-prescription sources, injection-site problems, unknown long-term effects, and lack of clinician monitoring 14 15.

CJC-1295, ipamorelin, and sermorelin

CJC-1295, ipamorelin, and sermorelin sit in the growth-hormone-axis family rather than the GLP-1 family. CJC-1295 is a growth-hormone-releasing hormone analog; in a small human study, it increased growth hormone and IGF-1 exposure after single injections, with study-attributed doses and monitoring performed by investigators 16.

Sermorelin is also a GHRH analog with a diagnostic history in growth-hormone testing 18. At Chia, sermorelin is available as injection, nasal spray, or tablets through licensed-provider review, and it can be part of the GLP-1 + Sermorelin protocol when appropriate; risks can include fluid retention, joint symptoms, glucose effects, and hormone-sensitive-condition concerns 18.

MOTS-c and other longevity peptides

MOTS-c is a mitochondrial-derived peptide studied for metabolic stress signaling, insulin sensitivity pathways, and aging biology. Human evidence remains early, and it should not be framed as a proven longevity medication 17.

For longevity peptides, the key question is not whether a compound sounds advanced; it is whether there is human evidence, a clear safety plan, and a licensed pharmacy source. Chia does offer longevity-focused medications such as NAD+, glutathione, and the Foundation Longevity protocol, but MOTS-c is not listed in our current catalog.

Which GLP-1 peptide works best for weight loss?

Semaglutide and tirzepatide have the strongest weight-management evidence among commonly discussed GLP-1-related medicines. In major trials lasting 68 to 72 weeks, both active ingredients produced more average weight loss than placebo, but individual results vary and gastrointestinal side effects were common 9 10.

In the STEP 1 trial, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention, and mean body weight decreased more with semaglutide than placebo over 68 weeks 9. Nausea, diarrhea, vomiting, and constipation were more common with semaglutide than placebo, so tolerability is part of the result, not a footnote 9.

In the SURMOUNT-1 trial, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly, and mean weight reduction was greater than placebo over 72 weeks 10. Gastrointestinal adverse events were the most common side effects and were usually reported during dose escalation 10.

There is no single best GLP-1 peptide for every person. A clinician weighs the reason for treatment, BMI, diabetes status, medications, thyroid-cancer history, MEN2 history, pancreatitis risk, gallbladder history, pregnancy plans, side-effect tolerance, route preference, access, and follow-up needs 1 2 3.

Are GLP-1 peptides safe?

GLP-1 peptides can be safe for many carefully selected patients, but they are prescription medicines with real risks. FDA labels list common stomach-related side effects and serious warnings, including medullary thyroid carcinoma and MEN2 contraindications for several products 1 2 3 5 6.

• Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, indigestion, and burping on GLP-1-related labels 1 2 3.
• Serious warnings include pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, hypersensitivity, and diabetic retinopathy complications for some products 1 2 3.
• Semaglutide, liraglutide, dulaglutide, and tirzepatide labels include contraindications for people with a personal or family history of medullary thyroid carcinoma or MEN2 1 2 3 5 6.
• Hypoglycemia risk can rise when GLP-1-related medicines are used with insulin or sulfonylureas 1 3.
• Weight-management GLP-1 medicines are generally not used during pregnancy, and product-specific labels include pregnancy-related guidance 2 3.

Seek urgent medical help for severe or persistent abdominal pain, signs of dehydration, allergic symptoms, or symptoms that feel dangerous. This article cannot tell whether a GLP-1 is safe for you; that requires a medical evaluation.

What are compounded GLP-1 peptides?

Compounded GLP-1 peptides are prescription medications prepared for an individual patient by a licensed compounding pharmacy, often called a 503A pharmacy. The core safety split is licensed medical care and licensed pharmacy dispensing versus no-prescription research-chemical vendors 15.

A compounded medication should not be called a generic version of Ozempic, Wegovy, Mounjaro, or Zepbound, and it should not be described as the same as those brand products. Trial outcomes are tied to the active ingredient, formulation, study dose, and study population; outcomes for compounded formulations are not established by FDA-evaluated clinical trials 9 10 15.

When our providers consider compounded semaglutide or tirzepatide, the decision is individualized. They review medical history, contraindications, current medicines, goals, side-effect risk, and follow-up needs before deciding whether a prescription is appropriate.

How do you get a GLP-1 peptide prescription?

GLP-1 peptide prescriptions start with a clinician evaluation, not a self-directed protocol. For chronic weight management, FDA labels commonly use BMI thresholds of ≥30, or ≥27 with at least one weight-related condition, depending on the product 2 3 5.

1. 1Clarify the treatment goal: type 2 diabetes, chronic weight management, cardiovascular risk reduction, or another question for clinical review.
2. 2Review eligibility, including BMI, weight-related conditions, diabetes status, and prior treatment history 2 3 5.
3. 3Screen for safety issues such as personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, gallbladder disease, kidney disease, pregnancy plans, severe gastrointestinal disease, and current diabetes medicines 1 2 3.
4. 4Choose a licensed care path, such as primary care, endocrinology, obesity medicine, or licensed telehealth.
5. 5Use a pharmacy source connected to a valid prescription and clinician follow-up, especially for injectable medicines 15.

How does GLP-1 treatment work at Chia?

At Chia, GLP-1 treatment starts with a 100% online health questionnaire and review by a licensed US provider. If treatment is clinically appropriate, our providers can prescribe compounded semaglutide injections or compounded tirzepatide tablets or injections through state-licensed US 503A compounding pharmacies, with home delivery.

We offer semaglutide injections, with plans currently starting at $249/month, and tirzepatide tablets or injections, with tablet plans currently starting at $249/month and injection plans currently starting at $299/month. Microdosing plans are available for semaglutide and tirzepatide when our providers determine that approach is appropriate.

If prescribed, medication is shipped to your door, and you can message your care team through the patient portal between visits. A prescription is never guaranteed; our providers decide based on your history, eligibility, safety factors, and treatment goals.

Frequently asked questions about GLP-1 peptides

Keep reading

GLP-1 Medications

GLP-1 Side Effects: What to Expect and How to Manage Them

Peptides

Peptide Cheat Sheet: Patient Reference to Common Peptides, Uses, and Dosing

Weight Loss

Peptide Injections for Weight Loss: What Actually Works